Stromal cell

Stimulating blood vessel formation with magnets

Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab

Wednesday, June 2, 2021 - 1:00pm

ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ) in patients with advanced cancers.

Key Points: 
  • ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ) in patients with advanced cancers.
  • ET via Zoom:
    Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.
  • Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies.
  • Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal

Tuesday, May 25, 2021 - 12:00pm

This is the basis for our ongoing investigation of remestemcel-L in the treatment of the severe lung inflammation including ventilator-dependent patients with COVID-19 ARDS.

Key Points: 
  • This is the basis for our ongoing investigation of remestemcel-L in the treatment of the severe lung inflammation including ventilator-dependent patients with COVID-19 ARDS.
  • Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor.
  • Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.
  • Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome.

RoosterBio Releases RoosterGEM™, Cell and Gene Therapy's First Complete Transduction Medium

Thursday, May 20, 2021 - 3:30pm

b'FREDERICK, Md., May 20, 2021 /PRNewswire-PRWeb/ --RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM , a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification.

Key Points: 
  • b'FREDERICK, Md., May 20, 2021 /PRNewswire-PRWeb/ --RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM , a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification.
  • RoosterGEM is configured to involve less manipulation by the biotechnician, saving process time and reducing opportunity for human error.
  • "Until now, our cell and gene therapy customers have been engineering their media from the ground up.
  • RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers.

RoosterBio Inc. Announces Winners of 2020 hMSC Development Grants

Thursday, March 11, 2021 - 2:00pm

FREDERICK, Md., March 11, 2021 /PRNewswire-PRWeb/ -- RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announced the 2020 Winners of our RoosterBio Development Award.

Key Points: 
  • FREDERICK, Md., March 11, 2021 /PRNewswire-PRWeb/ -- RoosterBio, a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, announced the 2020 Winners of our RoosterBio Development Award.
  • Each awardee will receive up to $12,000 in requested RoosterBio's hMSC and bioprocess media products in support of their respective proposed projects.
  • These systems have built-in design to streamline not just product development, but also to accelerate manufacturing processes for projects en route to early-stage clinical development.
  • RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers.

I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting

Thursday, March 11, 2021 - 1:00pm

Internally discovered by I-Mab, uliledlimab is a novel and highly differentiated antibody that targets the CD73 to modulate adenosine enriched cancer microenvironment.

Key Points: 
  • Internally discovered by I-Mab, uliledlimab is a novel and highly differentiated antibody that targets the CD73 to modulate adenosine enriched cancer microenvironment.
  • Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.
  • Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-1 and PD-(L)1 antibodies.
  • Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention

Wednesday, December 16, 2020 - 8:10pm

Under the proposed collaboration, Therapeutic Solutions International will contribute its existing expertise and intellectual property regarding adipose stem cell treatment of neuroinflammatory disorders, whereas Synova Life Sciences will provide access to its non-enzymatic stromal vascular fraction isolation device.

Key Points: 
  • Under the proposed collaboration, Therapeutic Solutions International will contribute its existing expertise and intellectual property regarding adipose stem cell treatment of neuroinflammatory disorders, whereas Synova Life Sciences will provide access to its non-enzymatic stromal vascular fraction isolation device.
  • The two parties aim to file an Investigational New Drug (IND) application to the FDA for initiating a clinical trial in patients at high risk of suicide.
  • "We are highly impressed by the superior speed, viability, and quality of SVF cells obtained using the Synova Life Sciences device as compared to other collagenase-based approaches.
  • "I look forward at working with the Team at Therapeutic Solutions International in advancing this novel utility of adipose derived stem cells," said John Chi, President and CEO of Synova Life Sciences.

NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors

Wednesday, December 9, 2020 - 9:05pm

LAIR1 is a collagen-binding inhibitory receptor expressed on immune cells1-2 that is implicated in immune suppression.

Key Points: 
  • LAIR1 is a collagen-binding inhibitory receptor expressed on immune cells1-2 that is implicated in immune suppression.
  • LAIR1 and collagens are upregulated in multiple cancer types3-7 where collagens are produced by activated stromal cells.
  • Designed to inhibit LAIR1 interactions with stromal-derived collagens, NGM438 has the potential to block this stromal checkpoint and restore anti-tumor immune responses.
  • NGM707 is a novel dual antagonist antibody that inhibits Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4).

Study Utilizing Imaging Mass Cytometry Details Changes in Lung Tissue Architecture at the Single-Cell Level in Patients with COVID-19

Thursday, November 19, 2020 - 1:32pm

This phenotype has been identified based on spatial analysis of lung tissue at the single-cell level throughout the disease continuum.

Key Points: 
  • This phenotype has been identified based on spatial analysis of lung tissue at the single-cell level throughout the disease continuum.
  • Results of the study , which have not yet been peer-reviewed, are available online through the medRxiv pre-print service.
  • This study utilized the Fluidigm reagents portfolio to label antibodies in a custom-designed panel of 36 biomarkers to capture different immune and stromal compartments of the lung.
  • Fluidigm, theFluidigmlogo, CyTOF, Hyperion, Imaging Mass Cytometry and IMC are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.

Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)

Thursday, September 3, 2020 - 2:00pm

FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform.

Key Points: 
  • FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the launch of its new allogeneic mesenchymal stromal cell (MSC) therapeutic platform.
  • Avalon plans to develop the MSC platform as a potential therapy for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and for bone marrow transplant related complications of acute graft versus host disease (aGVHD).
  • Mesenchymal stromal cells are typically isolated from the bone marrow, umbilical cord blood, fat tissue and other tissue types.
  • MSCs have the ability to suppress T-cell proliferation, cytokine secretion and regulate the balance of antibody-based and cell-based immune responses.